Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 22, 2022 07:00 ET | Source: Matinas BioPharma Holdings, Inc.

Matinas BioPharma to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and Hosted by M-Vest

BEDMINSTER, N.J., March 22, 2022 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on redefining the intracellular delivery of nucleic acids...
March 08, 2022 06:30 ET | Source: Matinas BioPharma Holdings, Inc.

Matinas BioPharma Reports Fourth Quarter and Full Year 2021 Financial Results and Operational Highlights

– Fifteen Patients Enrolled to Date in Cohort 4 of EnACT (all oral induction regimen); Topline Interim Data Expected Q3 2022 – – Potential Pathway to NDA Submission for MAT2203 with Confirmatory Data...
February 28, 2022 07:00 ET | Source: Matinas BioPharma Holdings, Inc.

Matinas BioPharma to Webcast Conference Call Discussing Fourth Quarter and Full Year 2021 Financial and Operational Results on March 8, 2022

BEDMINSTER, N.J., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on redefining the intracellular delivery of...
January 25, 2022 06:30 ET | Source: Matinas BioPharma Holdings, Inc.

Matinas BioPharma Provides Business Update and 2022 Strategic Outlook

– End of Phase 2 Meeting with FDA Provides Pathway to NDA Submission for MAT2203 Following Confirmatory Data to be Generated in an Additional Cohort; Cohort 5 in Ongoing EnACT Trial – – Cohort 4 of...
January 18, 2022 07:00 ET | Source: Matinas BioPharma Holdings, Inc.

Matinas BioPharma to Provide Corporate Update and 2022 Business Outlook on January 25, 2022

BEDMINSTER, N.J., Jan. 18, 2022 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on redefining the intracellular delivery of...
December 16, 2021 06:30 ET | Source: Matinas BioPharma Holdings, Inc.

Matinas BioPharma Announces Unanimous DSMB Approval to Progress into Fourth and Final Cohort of Patients in the EnACT Trial of MAT2203 (Oral Amphotericin B) for the Treatment of Cryptococcal Meningitis

– DSMB evaluated both safety and efficacy data in recommending cohort progression – – Data from third patient cohort confirm antifungal activity above pre-defined threshold target for success, while...
December 06, 2021 06:30 ET | Source: Matinas BioPharma Holdings, Inc.

Matinas BioPharma Appoints Thomas Hoover, M.B.A. as Chief Business Officer

BEDMINSTER, N.J., Dec. 06, 2021 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on improving the intracellular delivery of...
November 18, 2021 07:00 ET | Source: Matinas BioPharma Holdings, Inc.

Matinas BioPharma to Participate in 33rd Annual Piper Sandler Virtual Healthcare Conference

BEDMINSTER, N.J., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on improving the intracellular delivery of...
November 08, 2021 06:35 ET | Source: Matinas BioPharma Holdings, Inc.

Matinas BioPharma Reports Third Quarter 2021 Financial Results and Operational Highlights

– Positive efficacy and safety data announced from first two cohorts of patients in ongoing EnACT study of MAT2203 (oral amphotericin B) for treatment of cryptococcal meningitis; DSMB unanimously...
November 02, 2021 07:00 ET | Source: Matinas BioPharma Holdings, Inc.

Matinas BioPharma to Webcast Conference Call Discussing Third Quarter 2021 Financial and Operational Results on November 8, 2021

BEDMINSTER, N.J., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on improving the intracellular delivery of...